Latest Articles

Publication Date
Cyclana Bio Recruits First Patients in UK Endometriosis Study - Femtech Insider

Cyclana Bio Recruits First Patients in UK Endometriosis Study Femtech Insider

Published: May 20, 2026, 10:54 a.m.
GLP-1s May Help Reduce Endometrial Cancer Risk in Patients With Obesity and Metabolic Disease - Pharmacy Times

GLP-1s May Help Reduce Endometrial Cancer Risk in Patients With Obesity and Metabolic Disease Pharmacy Times

Published: May 19, 2026, 3:15 p.m.
Cyclana Bio granted Health Research Authority approval and recruits first patients for clinical observational study in endometriosis - News-Medical

Cyclana Bio granted Health Research Authority approval and recruits first patients for clinical observational study in endometriosis News-Medical

Published: May 19, 2026, 12:42 p.m.
Cyclana Bio Granted Health Research Authority Approval and Recruits First Patients for Clinical Observational Study in Endometriosis - BioSpace

Cyclana Bio Granted Health Research Authority Approval and Recruits First Patients for Clinical Observational Study in Endometriosis BioSpace

Published: May 19, 2026, 11:15 a.m.
FinancialContent - Cyclana Bio Granted Health Research Authority Approval and Recruits First Patients for Clinical Observational Study in Endometriosis - FinancialContent

FinancialContent - Cyclana Bio Granted Health Research Authority Approval and Recruits First Patients for Clinical Observational Study in Endometriosis FinancialContent

Published: May 19, 2026, 9:06 a.m.
Merck's drug helps uterine cancer patients live longer in late-stage trial - Reuters

Merck's drug helps uterine cancer patients live longer in late-stage trial Reuters

Published: May 18, 2026, 2 p.m.
Merck announces trial results for ADC that addresses unmet needs for patients with advanced endometrial cancer - PharmaLive

Merck announces trial results for ADC that addresses unmet needs for patients with advanced endometrial cancer PharmaLive

Published: May 18, 2026, 1:38 p.m.
The Evolving Role of the Pharmacist: From Clinical Pathways to Patient Advocacy - Pharmacy Times

The Evolving Role of the Pharmacist: From Clinical Pathways to Patient Advocacy Pharmacy Times

Published: May 18, 2026, 12:19 p.m.
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Business Wire

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Business Wire

Published: May 18, 2026, 10:45 a.m.
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Yahoo! Finance Canada

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Yahoo! Finance …

Published: May 18, 2026, 10:45 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!